HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Raises Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Outlook Therapeutics (NASDAQ:OTLK) and raises the price target from $1 to $2.
November 03, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics' price target has been raised from $1 to $2 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Outlook Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100